TY - JOUR
T1 - How I treat hepatitis C virus infection in patients with hematologic malignancies
AU - Torres, Harrys A.
AU - McDonald, George B.
N1 - Publisher Copyright:
© 2016 by The American Society of Hematology.
PY - 2016/9/15
Y1 - 2016/9/15
N2 - Hepatitis C virus (HCV) infection is not uncommon in cancer patients. Over the past 5 years, treatment of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and effective direct-acting antivirals (DAAs) have become the standard-ofcare treatment. Today, chronic HCV infection should not prevent a patient from receiving cancer therapy or participating in clinical trials of chemotherapy because most infected patients can achieve virologic cure. Elimination of HCV from infected cancer patients confers virologic, hepatic, and oncologic advantages. Similar to the optimal therapy for HCVinfected patients without cancer, the optimal therapy for HCV-infected patients with cancer is evolving rapidly. The choice of regimens with DAAs should be individualized after thorough assessment for potential hematologic toxic effects and drug-drug interactions. This study presents clinical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinical and laboratory presentations, complications, and DAA therapy. An upto-date treatment algorithm is presented.
AB - Hepatitis C virus (HCV) infection is not uncommon in cancer patients. Over the past 5 years, treatment of chronic HCV infection in patients with hematologic malignancies has evolved rapidly as safe and effective direct-acting antivirals (DAAs) have become the standard-ofcare treatment. Today, chronic HCV infection should not prevent a patient from receiving cancer therapy or participating in clinical trials of chemotherapy because most infected patients can achieve virologic cure. Elimination of HCV from infected cancer patients confers virologic, hepatic, and oncologic advantages. Similar to the optimal therapy for HCVinfected patients without cancer, the optimal therapy for HCV-infected patients with cancer is evolving rapidly. The choice of regimens with DAAs should be individualized after thorough assessment for potential hematologic toxic effects and drug-drug interactions. This study presents clinical scenarios of HCV-infected patients with hematologic malignancies, focusing on diagnosis, clinical and laboratory presentations, complications, and DAA therapy. An upto-date treatment algorithm is presented.
UR - http://www.scopus.com/inward/record.url?scp=84988432754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84988432754&partnerID=8YFLogxK
U2 - 10.1182/blood-2016-05-718643
DO - 10.1182/blood-2016-05-718643
M3 - Article
C2 - 27443290
AN - SCOPUS:84988432754
SN - 0006-4971
VL - 128
SP - 1449
EP - 1457
JO - Blood
JF - Blood
IS - 11
ER -